bioMérieux: organic growth almost 10% over first 9m
(CercleFinance.com) - bioMérieux has posted turnover of 1.
749 billion euros for the first nine months of 2018, up 4.5% as reported and up 9.8% at constant exchange rates and consolidation scope.
The In vitro diagnostics specialist explains that its growth has been boosted by three major growth drivers; i.e. molecular biology with the BioFire range, growth in the Asia-Pacific region and finally industrial applications.
Alexandre Mérieux, Chairman and Chief Executive Officer, said: “bioMérieux delivered another robust sales performance in the third quarter of 2018, with organic growth nearing 9%. These positive dynamics place the Group on track to achieving its financial objectives for the year.”
Copyright (c) 2018 CercleFinance.com. All rights reserved.
749 billion euros for the first nine months of 2018, up 4.5% as reported and up 9.8% at constant exchange rates and consolidation scope.
The In vitro diagnostics specialist explains that its growth has been boosted by three major growth drivers; i.e. molecular biology with the BioFire range, growth in the Asia-Pacific region and finally industrial applications.
Alexandre Mérieux, Chairman and Chief Executive Officer, said: “bioMérieux delivered another robust sales performance in the third quarter of 2018, with organic growth nearing 9%. These positive dynamics place the Group on track to achieving its financial objectives for the year.”
Copyright (c) 2018 CercleFinance.com. All rights reserved.